dockets: FDA-2024-P-5965

Regulatory dockets from Regulations.gov — containers for related documents and comments in a rulemaking proceeding.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id title docket_type last_modified object_id
FDA-2024-P-5965 FDA Requests the Food and Drug Administration (FDA) to take the following actions to accelerate access to Pritelivir, an investigational treatment for Herpes Simplex Virus (HSV) patients. 1. Grant Expanded Access (Compassionate Use) to Pritelivir under the existing Expanded Access Programs (EAP) to allow patients with severe or refractory HSV infections access to the drug. Nonrulemaking 2026-05-11T15:36:34Z 0b00006486895a12

Links from other tables